JP7599332B2 - クローディン６抗体及びがんを治療するための方法 - Google Patents

クローディン６抗体及びがんを治療するための方法 Download PDF

Info

Publication number
JP7599332B2
JP7599332B2 JP2020515692A JP2020515692A JP7599332B2 JP 7599332 B2 JP7599332 B2 JP 7599332B2 JP 2020515692 A JP2020515692 A JP 2020515692A JP 2020515692 A JP2020515692 A JP 2020515692A JP 7599332 B2 JP7599332 B2 JP 7599332B2
Authority
JP
Japan
Prior art keywords
seq
antibody
nos
cldn6
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020515692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536507A5 (enExample
JP2020536507A (ja
Inventor
コンクリン，ディラン
スレイモン，デニス
オブライエン，ニール
パラッツォロ，マイク
エウウ，エリカ ボン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of JP2020536507A publication Critical patent/JP2020536507A/ja
Publication of JP2020536507A5 publication Critical patent/JP2020536507A5/ja
Priority to JP2024099523A priority Critical patent/JP7869831B2/ja
Application granted granted Critical
Publication of JP7599332B2 publication Critical patent/JP7599332B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
JP2020515692A 2017-09-18 2018-09-18 クローディン６抗体及びがんを治療するための方法 Active JP7599332B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024099523A JP7869831B2 (ja) 2017-09-18 2024-06-20 クローディン６抗体及びがんを治療するための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762560143P 2017-09-18 2017-09-18
US62/560,143 2017-09-18
PCT/US2018/051610 WO2019056023A2 (en) 2017-09-18 2018-09-18 ANTIBODIES AGAINST CLAUDIN 6 AND METHODS OF TREATING CANCER

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024099523A Division JP7869831B2 (ja) 2017-09-18 2024-06-20 クローディン６抗体及びがんを治療するための方法

Publications (3)

Publication Number Publication Date
JP2020536507A JP2020536507A (ja) 2020-12-17
JP2020536507A5 JP2020536507A5 (enExample) 2021-10-28
JP7599332B2 true JP7599332B2 (ja) 2024-12-13

Family

ID=65723110

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020515692A Active JP7599332B2 (ja) 2017-09-18 2018-09-18 クローディン６抗体及びがんを治療するための方法
JP2024099523A Active JP7869831B2 (ja) 2017-09-18 2024-06-20 クローディン６抗体及びがんを治療するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024099523A Active JP7869831B2 (ja) 2017-09-18 2024-06-20 クローディン６抗体及びがんを治療するための方法

Country Status (22)

Country Link
US (4) US20200291111A1 (enExample)
EP (2) EP3826667B1 (enExample)
JP (2) JP7599332B2 (enExample)
KR (2) KR102793719B1 (enExample)
CN (2) CN111565744B (enExample)
AU (2) AU2018334434B2 (enExample)
BR (1) BR112020005196A2 (enExample)
CA (1) CA3076207A1 (enExample)
CZ (1) CZ2021138A3 (enExample)
DK (1) DK3826667T3 (enExample)
ES (1) ES2986343T3 (enExample)
FI (1) FI3826667T3 (enExample)
GB (1) GB202103867D0 (enExample)
HU (1) HUE067603T2 (enExample)
IL (2) IL313238A (enExample)
MX (2) MX428953B (enExample)
NO (1) NO20210351A1 (enExample)
PL (1) PL3826667T3 (enExample)
PT (1) PT3826667T (enExample)
SG (1) SG11202002114RA (enExample)
SI (1) SI3826667T1 (enExample)
WO (1) WO2019056023A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024150445A (ja) * 2017-09-18 2024-10-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン６抗体及びがんを治療するための方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3177215C (en) 2017-09-29 2026-06-09 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
KR102063341B1 (ko) * 2018-12-31 2020-01-07 다이노나(주) Icam-1에 특이적으로 결합하는 항체 및 그의 용도
CN119708241A (zh) 2019-02-15 2025-03-28 因特格尔莫来库乐有限公司 密封蛋白6抗体及其用途
DK3941946T3 (da) * 2019-03-20 2025-03-24 Univ California Claudin-6-antistoffer og lægemiddelkonjugater
WO2020191344A1 (en) * 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies
US11834512B2 (en) 2020-05-04 2023-12-05 The Regents Of The University Of California Inhibiting anti-ENPP1 antibodies
CN112386687B (zh) * 2020-12-09 2021-05-04 爱龄医美国际健康咨询服务(北京)有限公司 一种干细胞外泌体及其在药品和化妆品中的应用
WO2023091512A2 (en) * 2021-11-16 2023-05-25 Allakos, Inc. Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9
AU2023219174A1 (en) * 2022-02-09 2024-08-15 Sera Prognostics, Inc. Shbg and ibp4 antibodies and methods using same
CN120282987A (zh) 2022-11-30 2025-07-08 因特格尔莫来库乐有限公司 包括双特异性型式的针对紧密连接蛋白6的抗体
KR20260015262A (ko) 2023-05-25 2026-02-02 더 리전트 오브 더 유니버시티 오브 캘리포니아 암 치료를 위한 클라우딘-6 접합체의 투여량
JPWO2025075127A1 (enExample) * 2023-10-04 2025-04-10
TW202542202A (zh) * 2024-01-04 2025-11-01 美商翰森生物有限責任公司 抗體、抗原結合片段及其醫療用途
AU2025213885A1 (en) * 2024-02-01 2026-07-16 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-cldn6 antibody, antibody-drug conjugate thereof, and medical use thereof
WO2026084392A1 (ko) * 2024-10-14 2026-04-23 에이비엘바이오 주식회사 항-클라우딘6 항체 및 이의 용도
KR102953072B1 (ko) * 2025-08-20 2026-04-16 주식회사 누리사이언스 난소 및 난자의 성숙 및/또는 발달을 위한 조성물 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016533738A (ja) 2013-07-31 2016-11-04 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ 癌幹細胞を含む癌の診断および治療法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
DE3587500T2 (de) 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
WO1999040942A1 (en) 1998-02-10 1999-08-19 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
JP2003530297A (ja) 1998-10-16 2003-10-14 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， リプリゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｖｉｐアンタゴニストを用いる併用療法
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
WO2004033036A2 (en) 2002-10-04 2004-04-22 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
CA2672581A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
WO2008130158A1 (en) 2007-04-19 2008-10-30 Dong-A Pharmaceutical. Co., Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
AU2009203464A1 (en) * 2008-01-11 2009-07-16 Forerunner Pharma Research Co., Ltd. Anti-CLDN6 antibody
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
EP3026064B1 (en) * 2011-05-13 2018-10-17 Ganymed Pharmaceuticals GmbH Antibodies for treatment of cancer expressing claudin 6
AU2014346792A1 (en) * 2013-11-06 2016-06-02 Abbvie Stemcentrx Llc Novel anti-claudin antibodies and methods of use
CN106459165B (zh) * 2014-04-01 2021-04-20 拜恩科技细胞&基因治疗有限公司 密封蛋白-6特异性免疫受体和t细胞表位
SG11202002114RA (en) * 2017-09-18 2020-04-29 Univ California Claudin6 antibodies and methods of treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016533738A (ja) 2013-07-31 2016-11-04 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ 癌幹細胞を含む癌の診断および治療法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cancer Science，2009年09月，Vol.100, No.9，pp.1623-1630
The Journal of Biological Chemistry，2009年07月10日，Vol.284, No.28，pp.18863-18872

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024150445A (ja) * 2017-09-18 2024-10-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン６抗体及びがんを治療するための方法
JP7869831B2 (ja) 2017-09-18 2026-06-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン６抗体及びがんを治療するための方法

Also Published As

Publication number Publication date
MX2025012685A (es) 2025-11-03
SG11202002114RA (en) 2020-04-29
KR20250050137A (ko) 2025-04-14
CN111565744B (zh) 2024-12-31
IL273196B2 (en) 2024-11-01
IL313238A (en) 2024-07-01
AU2018334434A1 (en) 2020-04-02
MX428953B (es) 2025-11-13
IL273196A (en) 2020-04-30
CN118667021A (zh) 2024-09-20
US20250333501A1 (en) 2025-10-30
NO20210351A1 (en) 2021-03-18
EP3826667A2 (en) 2021-06-02
CA3076207A1 (en) 2019-03-21
EP4435009A3 (en) 2025-02-26
KR102793719B1 (ko) 2025-04-08
HUE067603T2 (hu) 2024-10-28
US20220372134A1 (en) 2022-11-24
ES2986343T3 (es) 2024-11-11
CN111565744A (zh) 2020-08-21
SI3826667T1 (sl) 2024-09-30
CZ2021138A3 (cs) 2021-09-15
KR20200070238A (ko) 2020-06-17
US20240400674A1 (en) 2024-12-05
BR112020005196A2 (pt) 2020-09-15
JP2024150445A (ja) 2024-10-23
AU2018334434B2 (en) 2025-01-23
PT3826667T (pt) 2024-08-02
MX2020002921A (es) 2020-09-28
JP2020536507A (ja) 2020-12-17
EP4435009A2 (en) 2024-09-25
EP3826667B1 (en) 2024-04-17
PL3826667T3 (pl) 2024-09-30
IL273196B1 (en) 2024-07-01
WO2019056023A2 (en) 2019-03-21
JP7869831B2 (ja) 2026-06-03
FI3826667T3 (fi) 2024-07-22
AU2025200467A1 (en) 2025-04-10
DK3826667T3 (da) 2024-07-22
WO2019056023A3 (en) 2019-05-16
GB202103867D0 (en) 2021-05-05
EP3826667A4 (en) 2022-07-27
US20200291111A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
US20250333501A1 (en) Claudin 4 and claudin 9 antibodies and methods of treating cancer
US11834499B1 (en) Claudin18 antibodies and methods of treating cancer
JP7682797B2 (ja) クローディン６二重特異性抗体
JP7682798B2 (ja) クローディン６抗体及び薬物複合体
HK40116828A (en) Claudin6 antibodies and methods of treating cancer
HK40053388A (en) Claudin6 antibodies and methods of treating cancer
HK40125763A (en) Claudin-6 antibodies and drug conjugates
BR122025023595A2 (pt) Proteína de ligação a antígeno, conjugado ou proteína de fusão, composição farmacêutica, seus métodos de produção, ácido nucleico e usos
HK40067893A (en) Claudin-6 antibodies and drug conjugates
HK40067893B (en) Claudin-6 antibodies and drug conjugates

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20210426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220920

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230620

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230919

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240620

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240701

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241203

R150 Certificate of patent or registration of utility model

Ref document number: 7599332

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150